EN DE

AMCO United Holding (0630) Fair Value & Analysis

Healthcare · HK · Market cap HK$209M

AU AMCO United Holding 0630 · HK
PriceHK$0.1100
Fair ValueHK$0.1200
Upside+9.1%
Quality62/100
Watch AMCO United Holding for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Highly profitable · 86.5% net margin
Low debt · generates free cash flow
Ranks above peers (10/12)
Wide moat 82/100
Evidence: High Range HK$0.0800 – HK$0.1500 Share as image

Fair value as of: Aug 13, 2026

From 21 valuation models · updated 2 days ago

Share price −34.9% over the past month.

A solid business, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • A fairly wide model range (HK$0.0800 to HK$0.1500) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$1.01 HK$0.0400 Fair Value HK$0.1200 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.0400 – HK$1.01 · fair‑value band HK$0.0800 – HK$0.1500 · the HK$0.1100 price screens below the HK$0.1200 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

AMCO United Holding (0630) currently trades at HK$0.1100, while our model-based Fair Value estimate is HK$0.1200, implying the stock looks roughly 9.1% fairly valued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, AMCO United Holding generated revenue of HK$68.4M at a net margin of 86.5%. Revenue grew 161.1% year over year. It earns a return on equity of 65.9%. Net debt stands at HK$17.7M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.0800 (bear case) to HK$0.1500 (bull case); at HK$0.1100, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 74% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at 9%, 0630 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$0.0500 HK$0.0600 HK$0.0800 80
Rev-Margin DCF HK$0.0500 HK$0.0800 HK$0.1200 74
ROIC Compounder HK$0.0600 HK$0.0700 HK$0.0800 72
All 21 models by family
DCF Models
FCF DCF HK$0.0500 HK$0.0600 HK$0.0900 38
5Y Revenue Exit HK$0.0500 HK$0.0800 HK$0.1200 39
5Y EBITDA Exit HK$0.0500 HK$0.0800 HK$0.1200 41
5Y P/E Exit HK$0.3700 HK$0.6200 HK$0.9300 38
10Y Revenue Exit HK$0.0500 HK$0.0600 HK$0.0800 36
10Y EBITDA Exit HK$0.0500 HK$0.0700 HK$0.0900 37
10Y P/E Exit HK$0.2100 HK$0.3500 HK$0.4900 35
Earnings-Based
Graham-Dodd HK$0.4200 HK$0.5100 HK$0.5700 54
EPV HK$0.0600 HK$0.0700 HK$0.0800 59
Multiples
P/E Multiple HK$0.7800 HK$1.04 HK$1.30 63
P/S Multiple HK$0.0800 HK$0.1100 HK$0.1300 58
P/B Multiple HK$0.2800 HK$0.3700 HK$0.4600 55
EV/EBIT HK$0.1100 HK$0.1500 HK$0.1900 53
EV/EBITDA HK$0.0700 HK$0.1000 HK$0.1300 54
EV/Revenue HK$0.0600 HK$0.0900 HK$0.1200 43
Asset-Based
NCAV (Graham) HK$0.0600 HK$0.0800 HK$0.1200 50
Growth DCF
Growth DCF HK$0.0500 HK$0.0600 HK$0.0800 80
Rev-Margin DCF HK$0.0500 HK$0.0800 HK$0.1200 74
Economic Profit
Residual Income HK$0.3800 HK$0.5900 HK$7.07 61
ROIC Compounder HK$0.0600 HK$0.0700 HK$0.0800 72
Growth Earnings
Growth-Adj P/E HK$0.5500 HK$0.7900 HK$1.03 68

Widest divergence: Growth Earnings (HK$0.7900) versus Growth DCF (HK$0.0600). Highest evidence: Growth DCF (80).

Notify me when 0630 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$68.4M
Revenue growth (YoY) +161%
Net margin 86.5%
Return on equity 65.9%
Free cash flow HK$8.1M FY2025
P/E ratio 3.6 as of Jul 2, 2026
More key figures
Operating margin 32.0%
EPS growth (YoY) +140%
Net debt HK$17.7M FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 62/100

Of which business quality 57 · Market factors (momentum, volatility) 7

Profitability 66
Margins and returns on capital today
Quality Growth 96
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 42
Balance sheet, leverage, solvency risk
Investment 51
Disciplined investing over empire-building
Low Volatility 20
Calm price path (market factor)
Momentum 2
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 40
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

AMCO United Holding Limited, an investment holding company, engages in the manufacturing of medical devices in Hong Kong, the People's Republic of China, and internationally. The company operates through Medical Products Business; Plastic Products Business; Money Lending Business; and Securities Investment Business segments.

Full company description

AMCO United Holding Limited, an investment holding company, engages in the manufacturing of medical devices in Hong Kong, the People's Republic of China, and internationally. The company operates through Medical Products Business; Plastic Products Business; Money Lending Business; and Securities Investment Business segments. It also sells plastic moulding products; provides money lending; and invests in securities. The company was formerly known as Guojin Resources Holdings Limited and changed its name to AMCO United Holding Limited in February 2012. AMCO United Holding Limited was incorporated in 1994 and is based in Central, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

AMCO United Holding reported revenue of HK$68.4M in FY2025 versus HK$71.9M in FY2021, a compound −1.3%/yr. Reported net income was HK$59.1M in FY2025.

Growth Quality 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
HK$68.4M
Latest YoY
+80.9%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+0.9%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.9%
Avg. growth/yr (25Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−8.6%
Revenue −1.3%/yr
FY21 HK$71.9M
FY22 HK$66.5M
FY23 HK$34.3M
FY24 HK$37.8M
FY25 HK$68.4M
Net income
FY21 −HK$18.1M
FY22 −HK$104M
FY23 −HK$2.8M
FY24 −HK$1.2M
FY25 HK$59.1M

Watch 0630: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AMCO United Holding · Fair Value
HK$0.1200 +9%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "AMCO United Holding Fair Value". https://www.fairvalue-calculator.com/stock/0630

Peer Group

Medical Instruments & Supplies · 202 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 62 · Above median
Fair Value upside +9% · Top 25%
Return on equity (TTM) 66% · Top 25%
Return on assets 4% · Above median
Net margin (TTM) 86% · Top 25%
Operating margin (TTM) 32% · Top 25%
Revenue growth 161% · Top 25%
Debt / equity 0.18× · Higher than median

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 3.6× · Cheaper than 75% of peers
P/B 1.75× · Cheaper than median
P/S (TTM) 3.06× · Pricier than median
P/FCF 3.3× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 45 · sector 0
FUTURE 100 · sector 26
PAST 100 · sector 25
HEALTH 91 · sector 96
DIVIDEND 0 · sector 36

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $401.27 $150.04 -63%
EssilorLuxottica Société anonyme 1EL €164.40 €68.55 -58%
Medline Inc MDLN $35.50 $30.15 -15%
Becton, Dickinson and Company BDX $181.41 $100.46 -45%
Alcon Inc ALC $73.58 $39.78 -46%
ResMed Inc RMD $226.00 $187.89 -17%
West Pharmaceutical Services, Inc WST $352.29 $141.58 -60%
Sartorius Stedim Biotech S.A DIM €180.30 €48.88 -73%
Coloplast A/S COLOB kr 429.70 kr 382.22 -11%
Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 ¥77.48 ¥27.22 -65%

Compare AMCO United Holding with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is AMCO United Holding (0630) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$0.1200 versus a price of HK$0.1100, about +9% (fairly valued).
What is the fair value of 0630?
Our model-based fair value for AMCO United Holding is HK$0.1200 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$0.1100.
What is the quality score of 0630?
AMCO United Holding has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of AMCO United Holding (0630)?
AMCO United Holding reported trailing-twelve-month revenue of about HK$68.4M (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 0630?
The net profit margin of AMCO United Holding is about 86.5%, meaning it keeps roughly 86.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track AMCO United Holding and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.